The GNRH1 Knockout SK-OV-3 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal population derived from the human SK-OV-3 ovarian adenocarcinoma cell line, with a targeted disruption of the GNRH1 gene. This loss-of-function model is produced by using CRISPR/Cas9 to introduce gene-disrupting edits across a bulk population, generating a heterogeneous mix of knockout alleles without single-cell cloning. The polyclonal format minimizes clonal selection artifacts, providing a robust tool for studying GNRH1-dependent processes in a genetically diverse cell pool. These cells serve as a versatile platform for functional genomics, drug discovery, and signaling pathway dissection in the context of ovarian cancer and reproductive endocrinology.
The SK-OV-3 parental line originates from the ascites of a patient with ovarian serous cystadenocarcinoma and is a widely used epithelial ovarian cancer model. These cells retain characteristic features of high-grade serous carcinoma, including TP53 mutation and chromosomal instability, and are commonly employed to investigate oncogenic signaling, metastatic behavior, and therapeutic resistance. The epithelial origin of SK-OV-3 makes it particularly relevant for studies of hormone-responsive gynecological malignancies. By introducing GNRH1 knockout into this background, researchers can interrogate the tumor-intrinsic functions of the GnRH system in a well-characterized ovarian cancer context.
GNRH1 encodes the hypothalamic decapeptide gonadotropin-releasing hormone, which acts as the master regulator of reproductive function. Upon binding to its cognate receptor GNRHR on pituitary gonadotropes, GNRH1 triggers Gq/11-mediated signaling cascades, including phospholipase C (PLCB)?Cmediated calcium mobilization and protein kinase C (PKC) activation, converging on the MAPK/ERK pathway (RAF1?CMAP2K1?CMAPK1/3). This leads to the phosphorylation of transcription factors such as CREB1 and c-Fos, driving the transcription of gonadotropin subunit genes FSHB, LHB, and CGA. Upstream, GNRH1 secretion is controlled by kisspeptin, neurokinin B, and dynorphin, and is modulated by sex steroids including estradiol and progesterone. In non-pituitary tissues, GNRH1?CGNRHR interactions can influence cell proliferation, apoptosis, and migration via similar intracellular cascades.
In SK-OV-3 cells, the GNRH1 knockout disrupts potential autocrine/paracrine GnRH signaling that may be implicated in ovarian cancer pathophysiology. While the role of GNRH1 in ovarian cancer is not fully defined, evidence suggests that GNRH1/GNRHR signaling can modulate MAPK/ERK activity and affect cellular responses to hormonal stimuli. Thus, this knockout polyclonal population provides a model to dissect the contribution of GNRH1 to tumor cell proliferation, survival, and invasion, as well as to assess responses to GnRH analogs used clinically. The polyclonal nature retains intra-population heterogeneity, enabling studies that better reflect the complexity of tumor cell signaling.
These cells are well-suited for a broad array of experimental workflows, including Western blotting and RT-qPCR to confirm target disruption, immunofluorescence for localization studies, and functional assays such as calcium imaging and phospho-ERK ELISA to assess signaling alterations. Proliferation (MTS assay) and apoptosis assays can evaluate the impact of GNRH1 loss on cell growth and death. Additionally, the T7E1 assay can verify CRISPR editing within the polyclonal pool. Research applications encompass ovarian cancer signaling studies, functional genomics in hormone-sensitive cancers, testing of GnRH agonists/antagonists, and reproductive endocrinology research. For further technical details and ordering information, please contact Ascent Research.
